{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:46:45Z","timestamp":1788378405643,"version":"build-2803163510"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Avelumab maintenance therapy improves survival in patients with advanced urothelial carcinoma who respond to first-line platinum-based chemotherapy. However, real-world evidence on its effectiveness and on the prognostic value of baseline clinical factors remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness of Avelumab maintenance therapy and to identify baseline prognostic factors associated with clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Multicenter prospective observational study including a retrospective cohort of patients treated before study initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Several Italian oncology centers participating between 2021 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 251 patients with advanced or metastatic urothelial carcinoma who received Avelumab maintenance therapy after achieving disease control with first-line platinum-based chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention(s) or Exposure(s)<\/jats:title>\n                    <jats:p>Avelumab maintenance therapy administered according to clinical practice. Baseline clinical variables, including ECOG performance status, metastatic sites, and corticosteroid use, were assessed for prognostic significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome(s) and Measure(s)<\/jats:title>\n                    <jats:p>Primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included overall response rate (ORR) and disease control rate (DCR). Prognostic factors were evaluated using multivariate Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median OS was 22.4 months, and median PFS was 7 months. The ORR and DCR were 26.75% and 69.30%, respectively. Independent predictors of worse OS were ECOG \u22651 (HR 1.57), bone metastases (HR 1.88), brain metastases (HR 7.02), and baseline corticosteroid use (HR 2.42). An exploratory prognostic score integrating ECOG status, bone metastases, and steroid use stratified patients into three groups with significantly different outcomes: median OS was 39.9 months (no adverse factors), 14.1 months (one factor), and 8.4 months (two or more factors), with corresponding ORRs of 33.6%, 28.0%, and 6.9%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this large real-world cohort, Avelumab maintenance confirmed its effectiveness and safety in advanced urothelial carcinoma. A simple exploratory prognostic score based on ECOG performance status, bone metastases, and baseline corticosteroid use successfully stratified patients by survival outcomes and may support personalized treatment strategies in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf388","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:49:25Z","timestamp":1763470165000},"source":"Crossref","is-referenced-by-count":5,"title":["Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-8237","authenticated-orcid":false,"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gambale","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence 50139,","place":["Italy"]},{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"De Gennaro Aquino","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence 50139,","place":["Italy"]},{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, IOV\u2014IRCCS , Padova 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Ospedale Arnas Civico , Palermo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaela Anna","family":"Vascotto","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence 50139,","place":["Italy"]},{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, IOV\u2014IRCCS , Padova 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Erbetta","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, IOV\u2014IRCCS , Padova 50139,","place":["Italy"]},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua , Padua,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Ospedale Arnas Civico , Palermo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mennitto","sequence":"additional","affiliation":[{"name":"Division of Oncology, University Hospital Maggiore della Carit\u00e0 , Novara,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 2, Ospedale Molinette Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino Corso Bramante 88 , 10126, Torino,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Nasso","sequence":"additional","affiliation":[{"name":"Medical Oncology, Ospedale Santa Corona , 17027 Pietra Ligure,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fanelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital of Udine , Udine,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Sorar\u00f9","sequence":"additional","affiliation":[{"name":"Ospedale di Camposampiero, U.O. Oncologia , Camposampiero,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Scolari","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Experimental and Clinical Sciences, University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana , Pisa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Salfi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana , Pisa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Oncologia Medica Universitaria Azienda Ospedaliera Universitaria Consorziale , Policlinico di Bari piazza Giulio Cesare, 11 , 70124, Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Puglisi","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale Maggiore , Trieste,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rametta","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, San Camillo Forlanini Hospital , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Doni","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence 50139,","place":["Italy"]},{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence 50139,","place":["Italy"]},{"name":"Clinical Oncology, Careggi University Hospital , Florence 50139,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025121103122194200_oyaf388-B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2025121103122194200_oyaf388-B2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"key":"2025121103122194200_oyaf388-B3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelialcarcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121103122194200_oyaf388-B4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.7326\/M22-1510","article-title":"Assessing heterogeneity of treatment effect in real-world data","volume":"176","author":"Segal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025121103122194200_oyaf388-B5","doi-asserted-by":"publisher","first-page":"102099","DOI":"10.1016\/j.clgc.2024.102099","article-title":"Neutrophil-TO-eosinophil ratio predicts the efficacy of avelumab in patients with advanced urothelial carcinoma enrolled in the MALVA study (Meet-URO 25)","volume":"22","author":"Gambale","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2025121103122194200_oyaf388-B6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014update and clarification: from the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025121103122194200_oyaf388-B7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121103122194200_oyaf388-B8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","article-title":"Real-world study of Avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment","volume":"8","author":"Barth\u00e9l\u00e9my","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2025121103122194200_oyaf388-B9","doi-asserted-by":"crossref","first-page":"100068","DOI":"10.1016\/j.esmorw.2024.100068","article-title":"READY: REAl-world data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma","volume":"5","author":"Antonuzzo","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol"},{"key":"2025121103122194200_oyaf388-B10","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1007\/s10238-023-01159-1","article-title":"The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study","volume":"23","author":"Mollica","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025121103122194200_oyaf388-B11","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1007\/s10238-023-01159-1","article-title":"The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study","volume":"23","author":"Mollica","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025121103122194200_oyaf388-B12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3332\/ecancer.2019.913","article-title":"How do clinicians rate patient\u2019s performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology","volume":"13","author":"Datta","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"2025121103122194200_oyaf388-B13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.advms.2021.07.005","article-title":"Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review","volume":"66","author":"Mojsak","year":"2021","journal-title":"Adv Med Sci"},{"key":"2025121103122194200_oyaf388-B14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3389\/fonc.2020.00789","article-title":"Current and emerging biomarkers predicting bone metastasis development","volume":"10","author":"Iuliani","year":"2020","journal-title":"Front Oncol"},{"key":"2025121103122194200_oyaf388-B15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.05.004","article-title":"Overcoming immunosuppression in bone metastases","volume":"117","author":"Reinstein","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025121103122194200_oyaf388-B16","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","article-title":"Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies","volume":"9","author":"Koyama","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121103122194200_oyaf388-B17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/03007995.2018.1532884","article-title":"Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population","volume":"35","author":"Bhowmik","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2025121103122194200_oyaf388-B18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer","volume":"145","author":"Sorial","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025121103122194200_oyaf388-B19","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","article-title":"Corticosteroids and cancer immunotherapy","volume":"29","author":"Goodman","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025121103122194200_oyaf388-B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2025121103122194200_oyaf388-B21","doi-asserted-by":"publisher","first-page":"CD013782","DOI":"10.1002\/14651858.CD013782.pub2","article-title":"Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer","volume":"1","author":"Sandford","year":"2023","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf388\/65415620\/oyaf388.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf388\/65415620\/oyaf388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf388\/65415620\/oyaf388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:12:30Z","timestamp":1765440750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf388\/8332238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf388","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,20]]},"article-number":"oyaf388"}}